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Ofﬁce of Biorepositories and Biospecimen Research, National Cancer Institute, Bethesda, MD
As a pathologist, I have been evaluating cancer resection
specimens throughout my career and have come to have a
deep appreciation of the challenges of surgical oncology.
Happily for patients, surgeons cure cancer on a fairly
regular basis by excising it with expert technique and
detailed knowledge of human anatomy and tumor biology.
The tissue resected by the surgeon and analyzed by the
pathologist is the source of crucial information that, in turn,
informs the decisions and actions of our medical oncology
colleagues.
As cancer medicine looks forward to a new era of
molecularly deﬁned cancer subtypes and targeted therapies,
however, the role of both surgeon and pathologist is
evolving to require an ever greater degree of professional
attention towards the surgical resection specimen. It is the
surgically resected tissue that possesses the molecular
information needed to deﬁne the speciﬁc molecular char-
acteristics of the patient’s tumor, the speciﬁc therapies to
which the tumor would be expected to respond, and even
the speciﬁc risks of adverse reactions to given therapies
predicted by the patient’s genetic make-up. This molecular
information forms the basis of the ‘‘personalized’’ approa-
ches envisioned for cancer patients in an age of molecular
medicine. The professional responsibility to assure that the
specimen’s molecular composition and integrity are safe-
guarded is shared by both the surgeon and the pathologist.
Current momentum towards molecular medicine is rapidly
elevating this professional responsibility to one of the most
important aspects of cancer patient care.
Currently, however, safeguarding the molecular integ-
rity or documenting surgical variables that impact the
molecular composition of the resection specimen is not
widely considered to be primary aspects of the surgeon’s
professional responsibility. Manipulations of the tissue
within the surgical procedure itself may have dramatic
effects on the molecular make-up of that tissue. However,
these manipulations are neither recorded nor controlled
when and where possible. Variables such as anesthesia type
and duration, drugs administered preoperatively and
intraoperatively, and devascularization/ischemia time for
the resected tissue may dramatically alter molecular pro-
ﬁles and/or molecular integrity. Once successfully
resected, the specimen may spend varying amounts of time
at room temperature in the surgical suite and/or holding
unit before being delivered to Pathology, which may fur-
ther alter the molecular composition and quality of the
tissue.
Without the surgeon’s extension of professional
responsibility to the resected tissue to control, when feasi-
ble, and track such variables, the advantages of personalized
adjuvant approaches may be lost to the patient. In molecular
medicine, the resected tissue becomes the major determi-
nant of all downstream therapy. Therefore, the care of the
specimen must be addressed co-equally with the care of the
patient. This elevated bar for ensuring tissue integrity and
molecular quality also must be addressed by pathologists.
The fresh specimen will need to be overseen by the
pathologist with the same immediacy and professional
attention. More than ever, surgeons and pathologists will be
required to work together closely to achieve the goal of
meeting the new standards of ‘‘specimen care’’ required for
molecular analysis.
Our knowledge about the affects of iatrogenic variables
such as surgical manipulation, intraoperative drug delivery,
and pathological handling on the molecular proﬁles that
reﬂect the biology in resected tissues is growing rapidly.
1–5
Postoperative tissue ischemia time, for example, has been
shown to alter gene and protein expression proﬁles within
minutesfollowingsurgicalexcisionincolectomyspecimens
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1–3 Not surprisingly, even
before resection has been completed, intraoperative manip-
ulations have been shown to markedly alter gene
transcription levels during radical prostatectomies.
4 The
effects of different peri- and intraoperative variables on
molecular proﬁles in different types of tissues are just
beginning to be understood, but it is clear that surgeons and
pathologists alike contribute signiﬁcantly to the ﬁnal
molecular composition and integrity of the resected tissue.
5
Procedures that maximize specimen quality respect the
fact that resected tissues are vital and biologically reactive.
Until they are ﬁxed or frozen, biospecimens are viable and
capable of reacting to physiological stress. They are a
living part of the patient from which they come and are
responsive to changes in temperature, perfusion, oxygen-
ation, and other physiological and biochemical variables,
both pre- and intraoperatively as well as postoperatively.
Typically, once a tumor is successfully resected, the sur-
geon’s attention turns to patient and relatively little is
directed towards the specimen. Unless an intraoperative
consultation such as a frozen section is requested and the
specimen is immediately addressed for this purpose, it may
sit unattended for varying periods of time before being
prepared for delivery to the pathology laboratory. The
conditions of delivery itself may vary, as may the imme-
diacy of the specimen handling once it has arrived in the
pathology laboratory. Furthermore, some of the newer
surgical techniques, such as robotically assisted prostate
resections, may further compromise the quality of the
resection specimen if it is allowed to remain in the oper-
ative site at body temperature for signiﬁcant amounts of
time after devascularization.
In this emerging age of molecular medicine, a new level
of awareness of and attention to ‘‘the state of the speci-
men’’ will be required by surgeons, operating room staff,
pathologists, and pathology staff. All play essential roles in
the series of events leading up to stabilization of the tissue
that impact its molecular make-up and molecular integrity.
Surgeons are the initiators and controllers of many of these
events and therefore represent the ‘‘gatekeepers.’’ The
powerful molecular analysis technologies now at our dis-
posal and the increasingly sensitive and speciﬁc analysis
platforms under development provide us with unprece-
dented abilities to deﬁne the molecular features of cells and
tissues. However, they also pose new risks by providing us
with the ability to derive the wrong answer with even
greater speed and accuracy unless the analytes are of high
quality and are derived from high-quality specimens. It is
our joint professional responsibility to follow procedures
that will ensure the quality of the biospecimen and to
document the specimen handling history for the patient’s
record.
In this dawning era of molecular medicine, where a
hard-won understanding of the molecular details of cancer
is leading to more powerful and accurate diagnostics and
therapeutics, I foresee surgeons and pathologists playing a
new and more pivotal role in cancer medicine. They are the
custodians of the specimens and therefore the molecules
that represent the personalized part of personalized medi-
cine. Surgeons will continue to cure cancer with greater
success rates through earlier detection and excision; but as
the custodians of the tissue, they will also be central to
improving cancer management through molecularly tar-
geted interventions.
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